Compulsory patent licensing and local drug manufacturing capacity in Africa;Octroi de licence obligatoire et capacité de production locale de médicaments en Afrique

Bulletin of the World Health Organization

Volumn 92, Issue 3, 2014, Pages 214-219

  Owoeye, Olasupo Ayodeji ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ARTICLE; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMIC COLLABORATION; HUMAN; LICENSING; MEDICAL ETHICS; ORGANIZATION AND MANAGEMENT; PATENT; PUBLIC HEALTH; WORLD TRADE ORGANIZATION;

EID: 84896830601     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.13.128413     Document Type: Article

References (31)

1. Nicol D, Owoeye O. Using TRIPS flexibilities to facilitate access to medicines. Bull World Health Organ 2013;91:533-9. doi: http://dx.doi.org/10.2471/BLT.12.115865 PMID:23825881
2. IMS Health [Internet]. Africa: a ripe opportunity. Understanding the pharmaceutical market opportunity and developing sustainable business models in Africa. London: IMS Health; 2012. Available from: http://www.imshealth.com/ims/Global/Content/Insights/Featured%20Topics/Emerging%20Markets/IMS_Africa_Opportunity_Whitepaper.pdf [accessed 28 September 2013].
3. Hestermeyer H. Human rights and the WTO: the case of patents and access to medicines. Oxford: Oxford University Press; 2007.
4. Cornish W, Llewelyn D. Intellectual property: patents, copyright, trade marks and allied rights. 6th ed. London: Sweet & Maxwell; 2007.
5. World Trade Organization [Internet]. Declaration on the TRIPS agreement and public health, adopted on 14 November 2001 (WT/MIN(01)/DEC/2). Geneva: WTO; 2013. Available from: http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm [accessed 28 September 2013].
6. World Trade Organization [Internet]. Least-developed country members-obligations under article70.9 of the TRIPS Agreement with respect to pharmaceutical products, decision of 8 July 2002(1) (WT/L/478). Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/art70_9_e.htm [accessed 5 December 2013].
7. World Trade Organization [Internet]. Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: General Council Decision of 30 August 2003 (WT/L/540). Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm [accessed 28 September 2013].
8. World Trade Organization [Internet]. Amendment of the TRIPS Agreement: General Council decision of 6 December 2005 (WT/L/641). Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm [accessed 28 September 2013].
9. World Trade Organization [Internet]. Extension of the transition period under Article 66.1 for least developed country members: decision of the Council for TRIPS of 11 June 2013 (IP/C/64). Geneva: WTO; 2013. Available from: http://www.wto.org/english/tratop_e/trips_e/ta_docs_e/7_1_ipc64_e.pdf [accessed 5 December 2013].
10. World Health Organization [Internet]. Cause-specific mortality: regional estimates for 2000-2011. Geneva: WHO; 2013. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html [accessed 28 September 2013].
11. 't Hoen E. The global politics of pharmaceutical monopoly power. Diemen: AMB Publishers; 2009. Available from: http://www.msfaccess.org/sites/default/files/MSF_assets/Access/Docs/ACCESS_book_GlobalPolitics_tHoen_ENG_2009.pdf [accessed 23 October 2013].
12. Cameron A, Ewen M, Auton M, Abegunde D. The world medicines situation 2011: medicines prices, availability and affordability (WHO/EMP/MIE/2011.2.1). Geneva: World Health Organization; 2011. Available from: http://www.who.int/medicines/areas/policy/world_medicines_situation/WMS_ch6_wPricing_v6.pdf [accessed 23 October 2013].
13. Laing R. The patent status of medicines on the WHO Model List of Essential Medicines. Geneva: World Health Organization, World Trade Organization & World Intellectual Property Organization; 2011. Available from: http://www.wto.org/english/tratop_e/trips_e/techsymp_feb11_e/laing_18.2.11_e.pdf [accessed 28 September 2013].
14. Novartis AG v. Union of India, SC Civil Appeal Nos. 2706-2716 of 2013. Supreme Court of India; 2013. Available from: http://www.globalhealthrights.org/asia/novartis-v-union-of-india-2/ [accessed 3 January 2014].
15. Anderson T. Tide turns for drug manufacturing in Africa. Lancet 2010;375:1597-8. doi: http://dx.doi.org/10.1016/S0140-6736(10)60687-3 PMID:20458781
16. Berger M, Murugi I, Buch F, Ijsselmuiden C, Moran M, Guzman J et al. Strengthening pharmaceutical innovation in Africa: designing strategies for national pharmaceutical innovation: choices for decision makers and countries. African Union, Council on Health Research for Development & The New Partnership for Africa's Development; 2010.
17. Patents Act, 2003 (Act 657). Accra: Parliament of the Republic of Ghana; 2003. Available from: http://www.wipo.int/wipolex/en/details.jsp?id=9426 [accessed 3 January 2014].
18. The Industrial Property Act, 2001. Nairobi: Government of Kenya, Kenya Industrial Property Office; 2001. Available from: http://www.wipo.int/wipolex/en/text.jsp?file_id=128383 [accessed 3 January 2014].
19. Patents and Designs Act 1990. In: Laws of the Federation of Nigeria, 1990, chapter 344. Available from: http://www.nigeria-law.org/Patents%20and%20Designs%20Act.htm [accessed 3 January 2014].
20. Law No. 31/2009 of 26/10/2009 on the Protection of Intellectual Property. Kigali: Government of the Republic of Rwanda, Ministry of Trade and Industry; 2009. Available from: http://www.wipo.int/wipolex/en/details.jsp?id=5249 [accessed 3 January 2014].
21. Medicines and Related Substances Amendment Act, 2002. Cape Town: Government of South Africa; 2002. Available from: http://www.info.gov.za/view/DownloadFileAction?id=68096 [accessed 3 January 2014].
22. African Union. Progress report on the pharmaceutical manufacturing plan for Africa: business plan. Addis Ababa: African Union Commission-UNIDO Partnership; 2012. Available from: http://www.unido.org/fileadmin/user_media_upgrade/Resources/Publications/Pharmaceuticals/PMPA_Business_Plan_Nov2012_ebook.PDF [accessed 23 October 2013].
23. International Finance Corporation. Impact: annual report 2012. Washington (DC): IFC; 2012. Available from: http://www1.ifc.org/wps/wcm/connect/2be4ef804cacfc298e39cff81ee631cc/AR2012_Report_English.pdf?MOD=AJPERES [accessed 28 September 2013].
24. African Union. Gaborone Declaration on a Roadmap towards Universal Access to Prevention, Treatment and Care. In: 2nd Ordinary Session of the Conference of African Ministers of Health (CAMH2), Gaborone, Botswana, 10-14 October 2005 (CAMH/Decl.1(II). Addis Ababa: AU; 2005. Available from: http://www.commit4africa.org/commitment/gaborone-declaration-roadmap-towards-universal-access-prevention-treatment-and-care [accessed 3 January 2014].
25. African Union. Draft pharmaceutical manufacturing plan for Africa (CAMH/MIN/7(III). Addis Ababa: AU; 2007.
26. Yu PK. Access to medicines, BRICS alliances, and collective action. Am J Law Med 2008;34:345-94. PMID:18697697
27. Palriwala A, Goulding R. Patent pools: assessing their value-added for global health innovation and access. Washington (DC): Results for Development Institute; 2012. Available from: http://healthresearchpolicy.org/assessments/patent-pools-assessing-their-value-added-global-health-innovation-and-access [accessed 23 October 2013].
28. The business of health in Africa: partnering with the private sector to improve people's lives. Washington (DC): International Finance Corporation; 2008. Available from: http://documents.worldbank.org/curated/en/2008/01/9526453/business-health-africa-partnering-private-sector-improve-peoples-lives [accessed 2 January 2014].
29. International Monetary Fund [Internet]. World economic outlook: growth resuming, dangers remain. IMF; 2012. Available from: http://www.imf.org/external/pubs/ft/weo/2012/01/ [accessed 2 January 2014].
30. Nicol D, Nielsen J. Opening the dam: patent pools, innovation and access to essential medicines. In: Pogge T, Rimmer M, Rubenstein K, editors. Incentives for global public health: patent law and access to essential medicines. New York: Cambridge University Press; 2010. pp. 235-62.
31. United Nations Office of the High Representative for the Least Developed Countries [Internet]. Landlocked developing countries and small island developing states: least developed countries. New York: UN-OHRLLS; 2013. Available from: http://www.unohrlls.org/en/ldc/25/ [accessed 28 September 2013].